vs

Side-by-side financial comparison of Viridian Therapeutics, Inc.\DE (VRDN) and Zhihu Inc. (ZH). Click either name above to swap in a different company.

Zhihu Inc. is the larger business by last-quarter revenue ($92.0M vs $70.6M, roughly 1.3× Viridian Therapeutics, Inc.\DE). Zhihu Inc. runs the higher net margin — 32.7% vs -49.0%, a 81.7% gap on every dollar of revenue.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

Zhihu is a Chinese social question and answer site and news aggregator. Originally based in Chengdu and with creators from Sichuan, China, the website launched on January 26, 2011. The number of registered users on Zhihu exceeded 10 million by the end of 2013, and reached 17 million as of May 2015, with 250 million monthly page views.

VRDN vs ZH — Head-to-Head

Bigger by revenue
ZH
ZH
1.3× larger
ZH
$92.0M
$70.6M
VRDN
Higher net margin
ZH
ZH
81.7% more per $
ZH
32.7%
-49.0%
VRDN

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
VRDN
VRDN
ZH
ZH
Revenue
$70.6M
$92.0M
Net Profit
$-34.6M
$30.1M
Gross Margin
53.6%
Operating Margin
-56.7%
Net Margin
-49.0%
32.7%
Revenue YoY
81958.1%
Net Profit YoY
54.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VRDN
VRDN
ZH
ZH
Q1 26
$92.0M
Q3 25
$70.6M
$92.6M
Q2 25
$100.1M
Q1 25
$100.6M
Q3 24
$120.4M
Q2 24
$128.5M
Q1 24
$133.1M
Q3 23
$140.1M
Net Profit
VRDN
VRDN
ZH
ZH
Q1 26
$30.1M
Q3 25
$-34.6M
Q2 25
Q1 25
Q3 24
$-1.3M
Q2 24
$-11.1M
Q1 24
$-23.0M
Q3 23
$-38.2M
Gross Margin
VRDN
VRDN
ZH
ZH
Q1 26
53.6%
Q3 25
61.3%
Q2 25
62.5%
Q1 25
61.8%
Q3 24
63.9%
Q2 24
59.6%
Q1 24
56.6%
Q3 23
53.7%
Operating Margin
VRDN
VRDN
ZH
ZH
Q1 26
Q3 25
-56.7%
-15.1%
Q2 25
-12.7%
Q1 25
Q3 24
-10.0%
Q2 24
-19.7%
Q1 24
-23.4%
Q3 23
-34.3%
Net Margin
VRDN
VRDN
ZH
ZH
Q1 26
32.7%
Q3 25
-49.0%
Q2 25
Q1 25
Q3 24
-1.1%
Q2 24
-8.6%
Q1 24
-17.3%
Q3 23
-27.2%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VRDN
VRDN
ZH
ZH
Cash + ST InvestmentsLiquidity on hand
$490.9M
$481.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$503.0M
$554.1M
Total Assets
$577.1M
$742.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VRDN
VRDN
ZH
ZH
Q1 26
$481.8M
Q3 25
$490.9M
$383.5M
Q2 25
$446.5M
Q1 25
$446.5M
Q3 24
$458.0M
Q2 24
$434.7M
Q1 24
$303.9M
Q3 23
$429.4M
Stockholders' Equity
VRDN
VRDN
ZH
ZH
Q1 26
$554.1M
Q3 25
$503.0M
$578.9M
Q2 25
$587.4M
Q1 25
$573.2M
Q3 24
$619.2M
Q2 24
$605.5M
Q1 24
$624.3M
Q3 23
$682.8M
Total Assets
VRDN
VRDN
ZH
ZH
Q1 26
$742.3M
Q3 25
$577.1M
$772.8M
Q2 25
$802.2M
Q1 25
$783.1M
Q3 24
$856.2M
Q2 24
$840.5M
Q1 24
$905.1M
Q3 23
$966.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VRDN
VRDN
ZH
ZH
Operating Cash FlowLast quarter
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VRDN
VRDN
ZH
ZH
Q1 26
Q3 25
$-84.6M
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q3 23
Free Cash Flow
VRDN
VRDN
ZH
ZH
Q1 26
Q3 25
$-84.7M
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q3 23
FCF Margin
VRDN
VRDN
ZH
ZH
Q1 26
Q3 25
-120.1%
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q3 23
Capex Intensity
VRDN
VRDN
ZH
ZH
Q1 26
Q3 25
0.2%
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons